432 related articles for article (PubMed ID: 31519114)
1. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
[No Abstract] [Full Text] [Related]
2. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
3. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
4. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
6. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
[TBL] [Abstract][Full Text] [Related]
9. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
[TBL] [Abstract][Full Text] [Related]
10. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Neokosmidis G; Cholongitas E; Tziomalos K
World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Huard K; Smith AC; Cappon G; Dow RL; Edmonds DJ; El-Kattan A; Esler WP; Fernando DP; Griffith DA; Kalgutkar AS; Ross TT; Bagley SW; Beebe D; Bi YA; Cabral S; Crowley C; Doran SD; Dowling MS; Liras S; Mascitti V; Niosi M; Pfefferkorn JA; Polivkova J; Préville C; Price DA; Shavnya A; Shirai N; Smith AH; Southers JR; Tess DA; Thuma BA; Varma MV; Yang X
J Med Chem; 2020 Oct; 63(19):10879-10896. PubMed ID: 32809824
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
[TBL] [Abstract][Full Text] [Related]
14. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Lawitz EJ; Bhandari BR; Ruane PJ; Kohli A; Harting E; Ding D; Chuang JC; Huss RS; Chung C; Myers RP; Loomba R
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):143-152.e3. PubMed ID: 34999207
[TBL] [Abstract][Full Text] [Related]
16. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
[TBL] [Abstract][Full Text] [Related]
18. Targeting ACC for NASH resolution.
Zhang XJ; Cai J; Li H
Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
[TBL] [Abstract][Full Text] [Related]
19. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
[TBL] [Abstract][Full Text] [Related]
20. A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase.
Lin Y; Yang M; Huang L; Yang F; Fan J; Qiang Y; Chang Y; Zhou W; Yan L; Xiong J; Ping J; Chen S; Men D; Li F
Cell Rep; 2023 Nov; 42(11):113453. PubMed ID: 37976162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
